Growth Factor News and Research

RSS

Freeze-dried tendon grafts loaded with gene therapy may provide repair injured tendons

According to study data published today in the journal Molecular Therapy, a new graft technique may provide the first effective framework around which flexor tendon tissue can reorganize as it heals.

9 Jan 2008

Three-drug cocktail improves outcomes in glioblastoma multiforme

New research at Wake Forest University Baptist Medical Center suggests that a three-drug cocktail may one day improve outcomes in patients with glioblastoma multiforme (GBM), a type of brain tumor with a dismal prognosis.

2 Jan 2008

Gene variation increases risk of liver tumor in patients with cirrhosis

A particular gene variation appears to significantly increase the risk that individuals with cirrhosis of the liver will go on to develop hepatocellular carcinoma (HCC), a liver tumor that is the third leading cause of cancer death.

2 Jan 2008

Drug effective for hepatitis C patients with low platelets

For patients with hepatitis C, having a low blood platelet count is a frequent complication associated with advanced disease.

2 Jan 2008

Bevacizumab found to improve survival for patients with advanced breast cancer

Inhibiting the growth of blood vessels that supply tumors slows the progression of metastatic breast cancer according to results of a large clinical trial of Avastin, an anti-angiogenic therapy.

28 Dec 2007

New mechanical insights into wound healing and scar tissue formation

New research published today in the Journal of Cell Biology illuminates the mechanical factors that play a critical role in the differentiation and function of fibroblasts, connective tissue cells that play a role in wound healing and scar tissue formation.

18 Dec 2007

Avastin shows promise for brain cancer

A clinical study conducted at Henry Ford Hospital on the use of a drug to extend the survival of patients with the most common and aggressive type of brain cancer, has yielded results that were significantly better than expected.

17 Dec 2007

Drug study for brain cancer shows promising results

14 Dec 2007

Bosutinib safe, effective for chronic myelogenous leukemia

A new drug for chronic myelogenous leukemia works for patients who have developed resistance to frontline therapy and causes fewer side effects than other medications in its class, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports at the 49th annual meeting of the American Society of Hematology.

12 Dec 2007

Researchers uncover delicate protein balance behind the immune system response

A team of researchers from the University of Pennsylvania School of Veterinary Medicine has identified the protein interactions involved in the immune system process that fights infection yet, in certain inflammatory diseases, runs amok and attacks friendly tissue.

10 Dec 2007

Keeping at-risk cells from developing cancer

Researchers at Johns Hopkins have discovered that cancers arising from epigenetic changes - in this case the inappropriate activation of a normally silent gene - develop by becoming addicted to certain growth factors.

10 Dec 2007

Growth factor receptor affects prostate cancer progression

Breeding mice with a gene for a cellular receptor that can be turned on and off-at will-not only enabled researchers at Baylor College of Medicine in Houston to show how prostate cancer progresses, but also provides a model for studying when a drug targeting a gene will have an effect on the cancer.

10 Dec 2007

Explanation on resistance to taxane class of drugs

Scientists have uncovered critical new details about the mechanisms that modulate the response of ovarian cancer cells to chemotherapy.

10 Dec 2007

Depression nearly triples the risk of death following a heart attack

...even when accounting for other heart attack risk factors, according to research presented at the American College of Neuropsychopharmacology (ACNP) annual meeting, which showed that among 360 depressed, post myocardial infarction patients followed for more than six years, those who did not recover from their depression in the first six months were more than twice as likely to die.

10 Dec 2007

Lymphatic vessel and lymph node function are restored with growth factor treatment

The frequent spread of certain cancers to lymph nodes often necessitates surgery or radiation therapy that damages the lymphatic system and can cause lymphedema, a condition of localized fluid retention that often increases susceptibility to infections.

4 Dec 2007

Hydrogen sulfide provides clues to a longer life

Hydrogen sulfide, or H2S, the chemical that gives rotten eggs their sulfurous stench - and the same compound that researchers at Fred Hutchinson Cancer Research Center successfully have used to put mice into a state of reversible metabolic hibernation - has now been shown to significantly increase life span and heat tolerance in the nematode worm, or C. elegans.

4 Dec 2007

Eltrombopag studied in Idiopathic Thrombocytopenic Purpura

There are estimated to be between 50,000 -- 100,000 individuals in the U.S. diagnosed with chronic Immune Thrombocytopenic Purpura (ITP), an autoimmune disease that dramatically reduces the number of platelets in their blood -- causing bruises, nosebleeds and, sometimes, life-threatening brain hemorrhages.

29 Nov 2007

Discovery of key acute myeloid leukemia gene

A gene called N-Myc leads a double life in certain white blood cells, helping to trigger a cancer called acute myeloid leukemia (AML) under some conditions while triggering apoptosis, or cell suicide, under other conditions, according to results of a mouse study done by investigators at St. Jude Children's Research Hospital.

27 Nov 2007

Wyeth receives European approval for TORISEL

Wyeth Pharmaceuticals, a division of Wyeth, has announced that the European Commission has approved TORISEL (temsirolimus) for the first-line treatment of patients with advanced renal cell carcinoma (RCC) who have at least three of six prognostic risk factors. TORISEL is the only approved cancer therapy that specifically inhibits the mTOR (mammalian target of rapamycin) kinase, an important regulator of cell proliferation, cell growth and cell survival.

27 Nov 2007